Deciphera Pharmaceuticals Stock Forecast, Price & News

Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

Is Deciphera Pharmaceuticals a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Deciphera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares.
View analyst ratings for Deciphera Pharmaceuticals or view top-rated stocks.

How has Deciphera Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DCPH stock has decreased by 80.9% and is now trading at $8.48.
View which stocks have been most impacted by COVID-19.

Are investors shorting Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 6,220,000 shares, an increase of 44.7% from the December 15th total of 4,300,000 shares. Based on an average daily trading volume, of 2,390,000 shares, the short-interest ratio is currently 2.6 days. Currently, 16.6% of the shares of the stock are sold short.
View Deciphera Pharmaceuticals' Short Interest.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for Deciphera Pharmaceuticals.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.29) by $0.08. The firm had revenue of $23.22 million for the quarter, compared to analyst estimates of $23.73 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 58.56% and a negative net margin of 300.00%. During the same quarter last year, the business posted ($1.13) EPS.
View Deciphera Pharmaceuticals' earnings history.

What price target have analysts set for DCPH?

10 equities research analysts have issued twelve-month price objectives for Deciphera Pharmaceuticals' shares. Their forecasts range from $10.00 to $78.00. On average, they anticipate Deciphera Pharmaceuticals' stock price to reach $33.63 in the next year. This suggests a possible upside of 296.5% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the following people:

• Steven L. Hoerter, President, Chief Executive Officer & Director
• Tucker Kelly, Chief Financial Officer, Treasurer & Executive VP
• Daniel L. Flynn, Chief Scientific Officer & Executive VP
• Stephen B. Ruddy, Chief Technical Officer
• Matthew L. Sherman, Chief Medical Officer & Executive Vice President

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Deciphera Pharmaceuticals' key competitors?

Some companies that are related to Deciphera Pharmaceuticals include Cryoport (CYRX), Schrödinger (SDGR), 23andMe (ME), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), Turning Point Therapeutics (TPTX), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Agios Pharmaceuticals (AGIO), Prothena (PRTA), Cassava Sciences (SAVA), Protagonist Therapeutics (PTGX), Xenon Pharmaceuticals (XENE) and Verve Therapeutics (VERV).
View all of DCPH's competitors.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $8.48.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals has a market capitalization of $495.92 million and generates $42.09 million in revenue each year. The company earns $-266.49 million in net income (profit) each year or ($4.74) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

Deciphera Pharmaceuticals employs 350 workers across the globe.

What is Deciphera Pharmaceuticals' official website?

The official website for Deciphera Pharmaceuticals is www.deciphera.com.

Where are Deciphera Pharmaceuticals' headquarters?

Deciphera Pharmaceuticals is headquartered at 200 SMITH STREET, Waltham MA, 02451.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at (781) 209-6400 or via email at [email protected].